Global

Even as the global economic roller coaster affects one of the country's dearest public institutions-the National Health Service-there is still reason for optimism in these times of austerity

GM's and investors find consensus in identifying innovation and productivity emerging from academia and small startups

The effect on pharma of the EU's Transparency Directive has been overly constraining, but will the mooted revisions offer any room to maneuver?

The pharmaceutical industry in Britain is a key sesctor in the full economic recovery of the country

The gap in perception is one of industry's biggest problems because it adds ballast to the idea that medicines are just a simple procurement item, writes William Looney.

The EC's latest proposals have thrown water on Europe's firey Direct-to-Consumer advertising debate. But is it enough to keep the flames at bay?

Richard Pops, Chief Executive Officer of Alkermes, explains how the company has established itself as a global, Irish-based firm.

GxP Cloud - business enablement for Life Sciences

Y.K. Hamied, PhD, Chairman, Cipla

Success in the emerging markets depends significantly on navigating the myths and mental traps.

Sir Michael Rawlins, Chairman of the UK National Institute for Health and Clinical Excellence

Garbo gets it ...

Big Pharma has increasingly turned to strategic outsourcing models to realize their own enterprise-wide strategic goals. Small- and medium-sized companies need to follow suit.

Can cooperative ties between Big Pharma, NGOs, government, and international organizations pay the freight in making the fight against neglected diseases a permanent fix in global health?

Pharm Exec talks to Dr. Mel Spigelman, President and CEO of the TB Alliance, about the organization's tuberculosis priorities.

Tata Consultancy Services has grown into one of the largest IT solutions providers in the world

Richard Barker, former Director General of ABPI, proposes a new agenda on how to restore public confidence in the value behind science.

Within an industry that traditionally moves at a slow pace, the rapidly changing playing field as required both Indian pharmaceutical companies, as well as MNCs, to adjust their strategies accordingly

Especially when payers come to the table holding the best cards - leaving industry second-guessing its strategy.

Q&A with Satish, Reddy, MD, COO of Dr. Reddy's Labs

When it comes to the emerging markets, executing a few key elements of success are more important than ever.

A Q&A with Kristin Peck, the drugmaker's Executive Vice President, Worldwide Business Development and Innovation.

What Big Pharma fails to see is how engagement in health policy is the biggest of reputation builders

Having progressively improved its financial standings over the past decade, this Eastern European market is now a bastion of potential-to the tune of $1.2 billion

HTAs are gridlocked by diverse national requirements, a lack of alignment on processes, and even on the value of their outcomes.